SynGenSys applies computational design strategies to engineer synthetic promoters with predictable performance characteristics for therapeutic and manufacturing applications. Professor David James ...
Learn how synthetic promoters bring innovation to gene expression, enhancing performance and safety in biotechnology ...
A new biosensor developed at the Department of Energy's Oak Ridge National Laboratory detects the emerging presence of fungus ...
CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company d ...
The OCU410ST Phase 2/3 pivotal confirmatory trial represents Ocugen’s second late-stage clinical program. Ocugen plans to submit the BLA for OCU410ST mid-2027 in alignment with its strategic goal of ...
Why Enveda, Faeth Therapeutics, Gilgamesh Pharma, and Argo Biopharma are among the most innovative companies in biotech right ...
Carbone called BAP1 a “paradox” because of its seeming ability to both promote and slow cancer, depending on the ...
Biomarker data for Sarepta Therapeutics’ RNA programs, licensed from Arrowhead Pharmaceuticals, are “competitive” and “strong ...
The Chinese biotech company received regulatory clearance for its BBM-H901 treatment, marking the country's inaugural gene ...
Eli Lilly and Regeneron are leading the push to treat congenital deafness with gene therapies, seeking a piece of a potential ...
Morning Overview on MSN
RNA-guided CRISPR tool turns genes on with dose control
Researchers have built a series of CRISPR-based platforms that can switch endogenous genes on and, just as critically, dial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results